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Abstract
A safe and effective HIV vaccine is required to significantly reduce the number of people becoming infected with HIV each
year. In this study wild type Mycobacterium bovis BCG Pasteur and an attenuated pantothenate auxotroph strain
(BCGDpanCD) that is safe in SCID mice, have been compared as vaccine vectors for HIV-1 subtype C Gag. Genetically stable
vaccines BCG[pHS400] (BCG-Gag) and BCGDpanCD[pHS400] (BCGpan-Gag) were generated using the Pasteur strain of BCG,
and a panothenate auxotroph of Pasteur respectively. Stability was achieved by the use of a codon optimised gag gene and
deletion of the hsp60-lysA promoter-gene cassette from the episomal vector pCB119. In this vector expression of gag is
driven by the mtrA promoter and the Gag protein is fused to the Mycobacterium tuberculosis 19 kDa signal sequence. Both
BCG-Gag and BCGpan-Gag primed the immune system of BALB/c mice for a boost with a recombinant modified vaccinia
virus Ankara expressing Gag (MVA-Gag). After the boost high frequencies of predominantly Gag-specific CD8
+ T cells were
detected when BCGpan-Gag was the prime in contrast to induction of predominantly Gag-specific CD4
+ T cells when
priming with BCG-Gag. The differing Gag-specific T-cell phenotype elicited by the prime-boost regimens may be related to
the reduced inflammation observed with the pantothenate auxotroph strain compared to the parent strain. These features
make BCGpan-Gag a more desirable HIV vaccine candidate than BCG-Gag. Although no Gag-specific cells could be detected
after vaccination of BALB/c mice with either recombinant BCG vaccine alone, BCGpan-Gag protected mice against a
surrogate vaccinia virus challenge.
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Introduction
Information in the 2010 UNAIDS Report on the global AIDS
epidemic indicates a global decline in HIV infection, observed as a
lower number of infections and deaths from AIDS. However there
is a strong warning in the Report that concerted efforts to improve
prevention of disease is of paramount importance as this will
contribute to prevention of infection. The quest for an HIV
vaccine should be an integral component of prevention strategies.
The precise requirements of an HIV vaccine needed for eliciting
protection against infection are as yet not known. Immune
responses to human immunodeficiency virus type 1 (HIV) that
participate in virus replication control, as observed in infected
individuals termed long-term non progressors or elite controllers,
include specific cellular responses that strongly target Gag [1,2].
Induction of such cellular HIV-specific immune responses is
therefore one of the favourable and necessary requirements of a
protective vaccination strategy [3]. There is abundant evidence
indicating heterologous prime-boost vaccine regimens that com-
bine the use of recombinant bacterial vaccine vectors and
recombinant virus vaccine vectors expressing HIV antigens and
HIV virus like particle protein vaccines induce robust HIV-specific
cellular immune responses [4–6].
Mycobacterium bovis bacillus Calmette-Gue ´rin (BCG) has been
explored as an HIV vaccine vector since the early 1990s [7,8].
BCG has a record of being safe in that it has been given to billions
of people worldwide with a very low incidence of serious
complications and importantly it induces long lasting immunity
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32769[9]. This knowledge has lead to many endeavours focussing on the
use of BCG and related mycobacteria as a live recombinant
vaccine vehicle [5]. A variety of viral, bacterial, parasitic and
human antigens when expressed in BCG and used in experimental
models yielded protective immunity against malaria parasites,
Lyme disease, pneumococcal infection, measles, tetanus, cutane-
ous leishmaniasis, cottontail rabbit papillomavirus, murine rota-
virus and listeriosis [10–15]. Mycobacterium smegmatis has also been
explored as a possible HIV vaccine vector and recently a lysine
auxotroph of BCG and a BCG strain expressing perfringolysin
(AERAS-401), have also been evaluated as possible vectors [16–
21]. Cell mediated responses as well as antibody responses to the
HIV insert, some of which provided protection against challenge,
have been detected in murine and macaque models when
mycobacterial vectors were used [16,22,23]. A major feature of
recombinant mycobacterial HIV vaccine vectors is their ability to
predominantly prime the immune system for a boost with either
recombinant adenovirus, recombinant poxviruses or proteins
[5,6,16,17,20,21,24,25]. The finding that non-human primates
primed with rBCG expressing simian immunodeficiency virus
(SIV) Gag and boosted with a recombinant replication deficient
vaccinia virus expressing the homologous antigen were protected
against a challenge with SHIV KS661c has inspired confidence in
BCG as a valuable vaccine vector for HIV genes [4].
We have shown that rBCG expressing HIV-1 subtype C Gag is
able to prime the immune system of baboons to a boost with
Pr55gag virus-like particles (Gag VLPs) with induction of high
magnitudes of Gag-specific CD8
+ and CD4
+ T cells as well as anti-
Gag antibodies [6]. A feature of this vaccine was utilization of an
episomal vector with the M. tuberculosis mtrA promoter (which is
down-regulated in culture and up regulated after uptake by
mammalian cells) to express Gag and the 19 kDa leader sequence
to direct the Gag protein to the bacterial cell membrane. This
vaccine was found to have a degree of genetic instability
characterised by deletions and rearrangements of the plasmid
and was thus unsuitable for manufacture.
In this study, a new plasmid expressing Gag was constructed.
Genetically stable rBCG vaccines expressing Gag, BCG-Gag and
BCGpan-Gag were generated using the Pasteur strain of BCG and
a pantothenate auxotroph of Pasteur (BCGDpanCD). Pantothenate
is a key precursor of coenzyme A and the acyl carrier protein and
is essential for many intracellular processes including fatty acid
metabolism, cell signalling and synthesis of polyketides and non-
ribosomal peptides [26]. A M. tuberculosis pantothenate, auxotroph
as well a BCG pantothenate auxotroph, have been studied in mice
and guinea pigs. Both showed a lack of virulence but protected
from challenge with M. tuberculosis [27,28]. BCG can cause
disseminated disease in immunocompromised individuals.
BCGDpanCD is safer in SCID mice and undergoes limited
replication in vivo despite persistence within the host. This study
evaluates the vaccines BCG-Gag and BCGpan-Gag for induction
of Gag-specific T cell responses with and without a MVA-Gag
boost. BCGpan-Gag was also tested for its ability to protect mice
against a surrogate vaccinia virus expressing Gag (VV-Gag)
challenge.
Results
Development of a genetically stable rBCG vaccine
The effect of codon optimizing the gag gene for BCG usage on
genetic stability of rBCG was then investigated. BCG was
transformed with the plasmids pHS300 and pRT106 expressing
codon optimised and uncodon optimised gag genes respectively.
Colonies produced by BCG transformed with plasmid pHS300
were larger than those transformed with pRT106, indicating that
codon-optimisation of the gag gene for expression in mycobacteria
had probably reduced the metabolic load generated by expression
of the viral antigen and thus improved the growth rate of the
recombinant BCG. Plasmid DNA isolated from BCG[pHS300]
and BCGDpanCD[pHS300] vaccine stocks contained deletions and
rearrangements. Restriction mapping and sequencing of plasmid
DNA isolated from these vaccines indicated that the p7p1p6
region of the gag gene, the hsp60 promoter and a portion of the lysA
gene were deleted in all the rBCG analysed (Figure 1 A & B). This
region of deletion varied between different vaccine stocks but, in
all cases, the hsp60 promoter was deleted. High levels of LysA
protein were detected by SDS-PAGE analysis of the BCG lysates
(data not shown). To determine whether the high levels of LysA
were contributing to the instability of the rBCG, the hsp60
promoter and lysA gene were deleted from the shuttle vector to
generate the plasmid pHS400 (expressing a codon optimised gag
gene), following which BCG[pHS400] (BCG-Gag) and
BCGDpanCD[pHS400] (BCGpan-Gag) were generated. Vaccine
stocks were found to be genetically stable and this stability was
maintained after in vitro passage for 30 generations (Figure 1 C &
D). The in vivo stability of BCG-Gag and BCGpan-Gag was also
confirmed by restriction enzyme mapping of plasmid DNA
isolated from rBCG recovered from mice splenocytes 6 weeks
post vaccination (data not shown). Growth rates of BCG-Gag and
BCGpan-Gag in broth supplemented with pantothenate were
comparable to those of the respective non-recombinant BCG
strains (data not shown). No growth of BCGDpanCD was observed
in the absence of pantothenate confirming its auxotrophic
phenotype.
Cellular responses, bacterial burden and histopathology
induced by rBCG vaccines
Vaccination of mice with the rBCG vaccines (10
7 cfu, i.p.)
resulted in spleen enlargement and an associated increase in the
total splenocyte yield compared to that of naive spleens (Figure 2A).
At 4 weeks post vaccination with BCG-Gag or a BCG-Control
(rBCG not expressing Gag), caused a 4.6–fold increase in
splenocyte numbers compared to that of naı ¨ve mice (p,0.01).
At 12 weeks post vaccination total splenocyte numbers were
always higher than that from naive spleens but the differences
were not statistically significant. The splenocyte yield in response
to BCGpan-Gag or BCGpan-Control (rBCGDpanCD not express-
ing Gag), vaccination was 2-fold greater (p,0.05) than that from
naive spleens at 4 weeks but not at 8 and 12 weeks post vaccination
(Figure 2A). The proportion of CD3
+ cells in the spleens following
vaccination with BCG-Gag or the control rBCG as determined by
flow cytometry was consistent at 4168% (n=10) but not
significantly different from the proportion of CD3
+ cells
(3964%, n=10) in spleens from mice vaccinated with BCGpan-
Gag or the control rBCG. These CD3
+ cell proportions post
rBCG vaccination compare with those from naı ¨ve spleens which
have a CD3
+ cell proportion of 4368% (n=10). Importantly, the
CD4
+:CD8
+ T cell ratio of the rBCG vaccinated mice was the
same as that of naive mice, 2.460.3 (n=10). Bacterial numbers in
the spleen after the rBCG vaccination declined over time and
there was no significant difference (p.0.05) in bacterial numbers
for the vaccines at any of the observed times (Figure 2B).
Histopathology analysis of liver sections 3 weeks post vaccination
revealed BCG-Gag induced a significantly larger number of
granulomas (p,0.05, week2; p,0.01, week 3) that were frequently
larger and contained more inflammatory cells than those isolated
from mice vaccinated with BCGpan-Gag (Figure 2C & 3). For
both BCG-Gag and BCGpan-Gag granulomas were well formed
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BCG was characterised by more prominent cellular infiltration
and hepatocyte damage than that induced by the DpanCD strain
(Figure 3).
rBCG vaccines expressing Gag prime the immune system
for a boost with MVA-Gag
Mice were vaccinated with the individual BCG vaccines
(10
5 cfu or 10
7 cfu) and Gag-specific immune responses investi-
gated using the IFN-c ELISPOT assay to detect individual
responses to a Gag CD8
+ peptide and two Gag CD4
+ peptides,
GagCD4(13) and GagCD4(17). No Gag-specific T cell responses
were detected at weekly intervals up to 12 weeks after vaccination.
To detect possible priming of the immune system by these rBCG
vaccines, groups of mice were primed on day 0 with the BCG
vaccines then boosted at week 8 or week 12 with MVA-Gag and
Gag peptide-specific immune responses were detected 12 days
after the boost (Figure 4).
BCGpan-Gag at a dose of 10
5 cfu or 10
7 cfu unlike BCG-
Gag, primed for a MVA-Gag boost given at week 8 (Figure 4).
Mean cumulative Gag-specific IFN-c ELISPOT responses (3
separate experiments) of 412623 sfu/10
6 splenocytes were
observed for a prime with 10
5 cfu BCGpan-Gag; and
835634 sfu/10
6 for a prime with 10
7 cfu BCGpan-Gag. These
mean cumulative Gag peptide responses were 2.8 fold (p,0.05)
and 5.8 fold (p,0.01) greater respectively than for a respective
control BCG prime and MVA-Gag boost (Figure 4). Both Gag
CD4
+ and CD8
+ peptide responses were boosted with Gag-
specific CD8
+ cells contributing 36% and 60% to the total mean
cumulative response for a dose of 10
5 cfu or 10
7 cfu BCGpan-
Gag respectively. In comparison the contribution of Gag-specific
CD8
+ cells to the total cumulative response for the control BCG
prime (10
5 cfu or 10
7 cfu) and MVA-Gag boost was 17% and
22% respectively (Figure 4).
BCG-Gag did prime the immune system to a MVA-Gag boost
given at week 12 after the BCG vaccine prime when the priming
dose was increased to 10
7 cfu. Comparison of Gag peptide
responses when the MVA-Gag boost was given at week 12 after a
prime with either BCGpan-Gag (10
7 cfu) or BCG-Gag (10
7 cfu) is
shown in Figure 4. For both vaccines Gag CD8
+ and CD4
+
Figure 1. Schematic maps and restriction enzyme digests of pHS300 and pHS400 plasmid DNA isolated from rBCG. (A) Schematic
map of plasmid pHS300. The deleted region, found in plasmid DNA isolated from vaccine stocks of rBCG, is indicated by a thick, dotted line. (B) Lanes
2 & 7 contain plasmid DNA prepared prior to transformation into BCG (positive controls). Lanes 3–6 and 8–11 contain pHS300 plasmid DNA isolated
from 4 different rBCG[pHS300] transformants. Plasmid DNA in lanes 2–6 was digested with restriction enzyme BglII and plasmid DNA in lanes 7–11
was digested with restriction enzymes EcoRV&ApaI. (C) Schematic map of plasmid pHS400. (D) Lanes 2 & 7 contain pHS400 plasmid DNA prepared
prior to transformation into BCG (positive controls). Lanes 3–6 and 8–11 contain plasmid DNA isolated from 4 different rBCG[pHS400] (rBCG-Gag)
transformants. Plasmid DNA in lanes 2–6 was digested with restriction enzyme BglII and plasmid DNA in lanes 7–11 was digested with restriction
enzymes XhoI&ApaI. Results were the same for rBCG and rBCGDpanCD.
doi:10.1371/journal.pone.0032769.g001
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(3 independent experiments) to the Gag peptides in the IFN-c
ELISPOT assay for either a prime with BCG-Gag or BCGpan-
Gag were similar, 9466212 sfu/10
6 splenocytes and
8476142 sfu/10
6 splenocytes respectively. These cumulative
Gag-peptide responses were approximately 3.4 fold higher
(p,0.01) than the responses for a control BCG vaccine prime/
MVA-Gag boost (Figure 4). However, when BCG-Gag was the
priming vaccine, Gag-specific CD4
+ cells contributed 82% and
Gag-specific CD8
+ cells 18% to this cumulative response,
indicating MVA-Gag predominantly boosted Gag-specific CD4
+
cells. In contrast when BCGpan-Gag was the prime Gag-specific
CD4
+ contributed 33% and Gag-specific CD8
+ cells 67% to the
cumulative Gag-specific response indicating MVA-Gag predom-
inantly boosted Gag-specific CD8
+ cells (Figure 4). The contribu-
tion of Gag-specific CD8
+ cells to the cumulative Gag-specific
response to a prime with both the control BCG vaccines followed
by a boost with MVA-Gag was approximately 24% (Figure 4).
Figure 2. Cellular responses to BCG-Gag and BCGpan-Gag. Groups of mice were vaccinated with BCG-Gag, BCG-Control, BCGpan-Gag or
BCGpan-Control (10
7 cfu, i.p.). (A) Total cell numbers in spleens harvested at the indicated times. Bars are mean total spleen cell numbers and
standard deviation of the mean for 10 mice per vaccine. Value for naive mice (unvaccinated) is also indicated. (B) Bacterial burden at the indicated
times determined by growth (3 weeks, 37uC) of spleen homogenates on 7H10 medium with kanamycin and also with pantothenate for the
BCGDpanCD strain. Bars are mean CFU per spleen and standard deviation of the mean for 3 mice per vaccine. (C) Quantitative analysis of liver
granuloma formation 3 weeks after infection. Bars are the mean and standard deviation of the mean of microscopic counts for 3 mice per vaccine.
Counts are from 10 fields per liver section with magnification 1006. This corresponds to 1 mm
2 per field, total 10 mm
2, which is approximately the
total area of a liver. Asterisks indicate (A) statistical significance compared to naive mice, or (C) compared to DpanCD strain (C); *,0.01; **,0.05;
Student’s t-test for unpaired data.
doi:10.1371/journal.pone.0032769.g002
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regimen induced high levels of Gag-specific IFN-c, TNF-a
and IL-6
A cytokine bead array assay quantified the level of IFN-c, TNF-
a and IL-6 produced by splenocytes after a prime with the BCG
vaccines and a boost with MVA-Gag given at week 12 after the
BCG vaccination (Figure 5). High levels of IFN-c were released
from splenocytes in response to Gag peptide stimulation
(Figure 5A). When BCG-Gag was the priming vaccine 10% of
the total Gag-specific IFN-c production of 58956473 pg/10
6
splenocytes (3 individual experiments) was from CD8
+ cells, while
for prime with BCGpan-Gag, CD8
+ cells contributed 63% to the
total Gag-specific IFN-c production of 66736328 pg/10
6 spleno-
cytes (3 individual experiments). These levels of IFN-c produced
Figure 3. Liver sections of mice vaccinated with rBCG. Histopathology examination of formalin fixed liver sections stained with haematoxylin
andeosinshowingthefrequencyofgranulomasinducedbythevaccines.Magnification2006,andarepresentativeviewfromoneof3 micepervaccine.
doi:10.1371/journal.pone.0032769.g003
Figure 4. IFN-c ELISPOT responses induced by a prime with the rBCG vaccine and MVA-Gag boost. Groups of mice were primed with
BCG-Gag (10
7 cfu) and BCG-Control (10
7 cfu), BCGpan-Gag (10
7 cfu or 10
5 cfu) or BCGpan-Control (10
7 cfu or 10
5 cfu) then boosted with MVA-Gag
(10
7 pfu, i.m.) at week 8 or week 12. Spleens were harvested 12 days after the boost, pooled from 5 mice per group and used in an IFN-c ELISPOT
assay with the indicated Gag-specific CD8
+ or CD4
+ peptides. Bars indicate the mean and standard deviation of the mean IFN-c ELISPOT response to
an individual Gag CD8
+ or Gag CD4
+ peptide for 3 separate experiments. Data are responses after subtraction of background responses which were
not more than 20 sfu/10
6 splenocytes. Asterisks indicate statistical significance of the mean IFN-c ELISPOT responses to the individual Gag peptides
obtained for a rBCG vaccine and MVA-Gag boost compared to that for the respective control rBCG vaccine prime MVA-Gag boost; *,0.01; **,0.05;
Student’s t-test for means of unpaired data.
doi:10.1371/journal.pone.0032769.g004
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greater (p,0.01) than those for a prime with the control BCG
vaccines followed by a MVA-Gag boost (Figure 5A). No Gag-
specific TNF-a above background responses could be detected for
a BCG-Gag prime and MVA-Gag boost. This is in contrast to
splenocytes from BCGpan-Gag primed and MVA-Gag boosted
mice that produced a total of 15326218 pg TNF-a/10
6
splenocytes (3 individual experiments) when stimulated with
Gag-peptides, with 31% being produced by Gag-specific CD8
+
cells. This TNF-a production was four times that of a prime with
the BCGpan-Control vaccine (Figure 5B). Splenocytes from BCG-
Gag primed and MVA-Gag boosted mice produced
107716520 pg IL-6 and all from Gag-specific CD4
+ cells (3
individual experiments). This Gag-specific IL-6 production was 8-
fold above (p,0.01) that of a prime with the BCG-Control
vaccine. A prime with BCGpan-Gag elicited 4945 pg IL-6/10
6
splenocytes with approximately equal quantities from Gag-specific
CD8
+ and CD4
+ cells. This Gag-specific IL-6 production was 3-
fold above (p,0.05) that of a prime with the BCGpan-Control
vaccine (Figure 5C).
BCGpan-Gag protects against a VV-Gag challenge
The data from the immune assays suggest BCGpan-Gag primes
predominantly Gag- specific CD8
+ cells. Thus the ability of
BCGpan-Gag to protect mice against a VV-Gag challenge was
assessed. Similar titres of VV-NYCBH were measured in mice that
were challenged with this control vaccinia virus after vaccination
with either the BCGpan-Gag, the BCGpan-Control vaccine or the
Figure 5. Gag-specific IFN-c, TNF-a and IL-6 responses induced by a rBCG prime and MVA-Gag boost. Groups of mice were vaccinated
with10
7 cfu BCG-Gag, BCG-Control, BCGpan-Gag or BCGpan-Control then boosted with MVA-Gag (10
7 pfu) at week 12. Spleens were harvested 12
days after the boost and pooled from 5 mice per group and stimulated in culture with the indicated Gag-specific CD8
+ and CD4
+ peptides. Bars
indicate the Gag peptide-specific cumulative cytokine response and blocks within each bar indicate the mean and standard deviation of the mean
cytokine response for 3 individual experiments to either a Gag CD8
+ or Gag CD4
+ peptide. All responses are after subtraction of background
responses of not more than 2 pg per 10
6 splenocytes. Asterisks indicate statistical significance of the cumulative cytokine response for the rBCG
vaccine compared to the control rBCG vaccine. *,0.01; **,0.05; Student’s t-test for unpaired data.
doi:10.1371/journal.pone.0032769.g005
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vaccines nor the resuspension medium provided nonspecific
vaccinia protection. In addition no non-specific protection against
VV-Gag was observed in mice vaccinated with the BCGpan-
Control vaccine or the BCG vaccine resuspension medium as
similar VV-Gag titres were obtained after a VV-Gag challenge
(Figure 6). However for mice vaccinated with BCGpan-Gag then
challenged with VV-Gag, no virus was recovered from the ovaries,
which translates to .7 log protection compared to that of a
vaccination with the BCGpan-Control or the BCG vaccine
resuspension medium followed by VV-Gag challenge.
Discussion
In this study BCG has been evaluated as an HIV vaccine vector
expressing Gag. The DpanCD BCG auxotroph was compared to
the wild type BCG as a vaccine vector as this strain has been
shown to be less virulent than the wild type strain in mice and
guinea pigs. The observation that BCG vaccination of HIV
positive children has accounted for mycobacterial disease in a
proportion of these immunocompromised subjects strongly
indicates the need for the development of safer mycobacterial
vectored vaccines [29,30]. Second generation auxotroph strains of
M. tuberculosis and BCG have thus been generated for use against
tuberculosis. Deletion of genes important for mycobacterial
growth such as lysA, leuD, met and panCD results in attenuated
growth in vivo with a consequent improved safety profile in
immunocompromised animals and concomitant enhanced or
comparable protection of mice and guinea pigs against M.
tuberculosis challenge compared to the parent strain [28,31–34].
rBCG expressing listeriolysin or perfringolysin O have also been
shown to have improved safety in SCID mice as compared to the
wild type strain [13,35]. Safety issues are also of concern with the
use of BCG as a HIV vaccine vector and this has led to auxotroph
BCG strains being considered as alternative vectors for immuo-
compromised individuals [28]. These mutant strains do not show
compromised immunogenicity in animal studies [20,24,36]. The
DpanCD BCG auxotroph has previously been shown to require
pantothenate supplementation to grow in human macrophages
and is nonpathogenic in SCID mice. When used to express the M.
tuberculosis 30 kDa major secretory protein in the development of a
candidate TB vaccine, rBCG(panCD)30, this auxotroph was better
tolerated at higher doses than the parent strain and provided
protection comparable to that of BCG in guinea pigs [28]. In vitro
our BCGpan-Gag vaccine grew at a rate similar to BCG-Gag in
the presence of pantothenate supplementation in broth culture.
Deletion of the hsp60 promoter and lysA gene from the vector
resulted in genetically stable BCG and DpanCD BCG auxotroph
vaccines, both in vitro and in vivo. No plasmid deletions and
rearrangements were observed. This modification of the plasmid
together with the use of a codon optimised gag gene was essential to
prevent deletion of p7p1p6 from the C-terminus of Gag. Plasmid
instability has previously been shown to be associated with the
activity of the strong hsp60 promoter [37–39]. It is important to
have a vaccine that includes p7p1p6 as HIV infected individuals
do mount immune responses to this Gag region [40]. The BCG
Figure 6. Protection from a Vaccinia Virus-Gag challenge by BCGpan-Gag. Challenge of mice vaccinated with BCGpan-Gag or BCGpan-
Control vaccine with VV-Gag or VV-NYCBH. Groups of 10 mice were vaccinated with BCGpan-Gag (2610
6 cfu), BCGpan-Control (2610
6 cfu) or
resupension medium on day 0 and day 28. Two weeks later half the mice in each group were challenged with VV-Gag or VV-NYCBH (1610
6 pfu) and
ovaries harvested 5 days later to determine virus titres. Bars indicate the mean and standard deviation of the mean virus titre.
doi:10.1371/journal.pone.0032769.g006
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activity. The observed genetic stability of our vaccines may be
attributed to two factors, fusion of the gag gene to the M. tuberculosis
19 kDa signal sequence, to assist with transport of the Gag protein
to the surface of the mycobacterium, and control of HIV-1 gag
gene expression by the M. tuberculosis mtrA promoter, which is up-
regulated after uptake of rBCG by phagocytosing cells [6,37,41–
43]. In vivo expression of HIV-1 Gag was not assessed in this study,
however both BCG-Gag and BCGpan-Gag primed the immune
system for a MVA-Gag boost, indicating that Gag presentation
must have occurred after cellular uptake of the rBCG vaccines.
Comparison of immune responses to Gag induced by BCG-Gag
and BCGpan-Gag indicated that although no Gag-specific T cells
could be detected in response to the vaccines alone, Gag-specific
responses were detected after the MVA-Gag boost. These
responses were not due to BCG-dependent adjuvant activity as
Gag-specific T cell responses induced by a MVA-Gag vaccination
alone were not significantly different from that observed after a
prime with the BCG-Control or BCGpan-Control vaccines and a
MVA-Gag boost (data not shown). Thus both vaccines did appear
to prime the immune system.
In addition BCGpan-Gag induced Gag-specific responses that
protected against a surrogate vaccinia virus-Gag challenge.
Greater than 7 logs of protection were seen in the vaccinia virus
challenge when mice were immunised with BCGpan-Gag.
Protection from challenge in this model is associated with CD8
+
responses [44] and therefore this result indicated that the HIV-1
specific CD8
+ T cell immune response induced with BCGpan-Gag
was protective.
Data from several studies indicate mycobacterial vaccines prime
the immune system for a booster vaccine [5,6,17,19,20,24].
Although a pro-apoptotic M. tuberculosis DlysADsecA2 mutant and
a BCG Pasteur lysA auxotroph have generated CD8
+ cells to the
HIV plasmid insert, an inability to detect responses or detection of
low responses to an HIV or SIV insert delivered by BCG or BCG
and M. tuberculosis single and double auxotrophs have generally
been reported in murine and non-human primate vaccine studies
[19,36]. Mechanisms of immune system priming by BCG are
associated with in vivo replication rates and levels and duration of
antigen expression in the bacteria [45]. BCG replication after
vaccination is slow which favours low levels of antigen expression
followed by low levels of antigen presentation [46]. Subsequently
low magnitudes of induced antigen specific T cells that
differentiate to the memory phenotype soon after vaccination
are generated and are stimulated by the booster vaccine [47].
The responses to a MVA-Gag boost that we detect after a prime
with BCG-Gag or BCGpan-Gag indicate Gag-specific T cells were
probably induced by the BCG vaccines and it is possible the
memory phenotype of these cells prevented their detection in the
IFN-c ELISPOT assay [47]. Gag-specific CD4
+ cells were
predominantly generated to the boost after a BCG-Gag prime.
In contrast BCGpan-Gag primed for a boost of predominantly
Gag-specific CD8
+ cells. These vaccines were given at a dose of
10
7 cfu per mouse. MVA-Gag boosted primary Gag-specific
CD8
+ and CD4
+ cells as early as 8 weeks post the BCGpan-Gag
prime; but this was not achieved with a BCG-Gag prime. The
overall greater inflammation generated by the wild type strain may
have prevented the development of the secondary responses.
These Gag-specific T cells produced IFN-c, TNF-a as well as IL-
6, cytokines which are proposed to be necessary for control of HIV
infection [48–50]. Induction of a Gag-specific CD4
+ response may
be expected as BCG per se induces CD4
+ cell responses in mice
which would influence predominant insert-specific CD4
+ cell
development [51]. However a CD4
+ response does assist CD8
+
development [52,53]. Induction of Gag-specific CD4
+ and CD8
+
cells by the BCGpan-Gag prime and MVA-Gag boost regimen is a
required favourable vaccine response and suggests both MHC
class I and II presentation of the antigen occurs with generation of
CD8
+ cells a consequence of possible efficient cross priming by the
BCG vaccine.
As inflammatory signals from BCG are expected to also
influence the characteristics of the immune response to the HIV
insert the reduced inflammation caused by the BCGDpanCD strain
may account for the immune response to the gag gene seen as both
Gag-specific CD8
+ and CD4
+ cells [48]. This modulation of
inflammation by the BCGDpanCD strain vaccination was observed
in this study as a reduction in early expansion of CD3
+ cells as well
as a reduction in granuloma size and number compared to the
parent strain. Despite this lower cellular response to the
BCGDpanCD strain, bacterial replication was similar to that of
the wild-type strain. Similar reduced pathology with constraint of
bacterial growth has been observed in mice in response to a M.
tuberculosis DpanCD mutant as well as the M. tuberculosis whiB3 and
sigH mutants [33,54,55]. Deletion of the panC and panD genes
inhibits the synthesis of pantothenate which is one of the
requirements for protection of bacteria from oxidative stress. In
addition there is a decrease in phospholipid and intermediate
amino acid and polyketide biosynthesis through deletion of the
panC and panD genes. This lack of pantothenate biosynthesis
associated with decreased inflammation may play a major role in
the orchestration of immune responses to Gag expressed by the
BCGpan-Gag vaccine.
In conclusion this is the first study using the BCG DpanCD
auxotroph as an HIV vaccine vector and shows that, when used
as a vector for the gag gene, HIV-specific T cells are induced that
protect against vaccinia virus surrogate challenge and can be
boosted to a high level with a heterologous booster vaccine. The
reduced inflammation induced by the auxotroph appears to be
an important factor in the generation of this broad immune
response to the HIV insert. Thus, the BCGpan-Gag vaccine
appears, through its combined features of genetic stability, safety
in immunocompromised mice and ability to elicit CD8
+ and
CD4
+ T cell responses in heterologous prime boost vaccine
regimes, to be a more promising HIV vaccine candidate than
BCG-Gag.
Methods
Construction of recombinant BCG (rBCG) expressing Gag
and vaccine preparation
Wild type M. bovis BCG Pasteur1172 P2 (BCG) (supplied by the
Statens Seruminstitut, Denmark) and M. bovis BCG mc
26000
(BCGDpanCD), a pantothenic acid auxotroph strain derived from
BCG Pasteur (constructed as per the M. tuberculosis DpanCD mutant
[33]), were grown on Middlebrook 7H10 agar supplemented with
10% oleic acid-albumin-dextrose-catalase (OADC) and 0.5%
glycerol (7H10) or in Middlebrook 7H9 broth supplemented with
10% OADC, 0.2% glycerol and 0.025% tyloxapol (7H9) on rollers
(4 rpm) at 37uC. Kanamycin (10 mg/ml) was included in the
media for plasmid selection where required. Media was supple-
mented with pantothenate (48 mg/ml) and hygromycin (50 mg/ml)
for the growth of BCGDpanCD.
The shuttle vector pHS300 expressing HIV-1 Gag was
constructed as follows: the full length HIV-1 subtype C gag gene
[56] was codon optimised for use in BCG and cloned into the ApaI
and ClaI restriction sites of plasmid pCB119, thus fusing the gag
gene to the nucleotides encoding the M. tuberculosis 19 kDa signal
sequence and placing it under the control of the M. tuberculosis mtrA
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the hsp60 promoter and lysA gene from vector pHS300 (Figure 1).
The shuttle vectors pHS300, pHS400, pRT106 [6] and
pCONEPI (vector not containing gag, Genbank accession
DQ191755) were introduced into BCG and BCGDpanCD by
standard mycobacterial electroporation procedures to generate
rBCG [57]. The rBCG were plated on 7H10 media plus
kanamycin (10 mg/ml) with the appropriate supplements and
incubated at 37uC for approximately 3 weeks. Vaccine stocks were
prepared by culturing selected recombinants in 5 ml 7H9 media,
then inoculating 100 ml 7H9 media in a roller bottle and growing
cells until mid-logarithmic phase (,OD600 0.8). The cultures were
then harvested and the pellets resuspended in resuspension
medium (0.85% NaCl; 10% glycerol; 0.025% tyloxapol) to give
a final OD600=10 which is equivalent to a concentration of
1610
9 cfu/ml. The vaccine stocks were stored at 280uC till
required. To confirm in vitro genetic stability plasmid DNA was
recovered from vaccine stocks and mapped with restriction
enzymes and the HIV-1 gag gene was sequenced. Prior to
vaccination the vaccines were defrosted on ice and passed through
a 21 gauge syringe needle 10 times in order to disperse clumps just
prior to injection.
In vitro and in vivo stability of the rBCG
To assess stability of the rBCG, cultures were passaged daily for
approximately 30 generations in liquid media with and without
antibiotic selection. Aliquots of the culture were frozen at 280uC
in 15% glycerol prior to each passage. The number of colony
forming units obtained after plating suitable dilutions of the
cultures on 7H10 media with and without kanamycin (10 mg/ml)
were compared to determine plasmid stability. To assess the
genetic stability of the rBCG, plasmid DNA was recovered after 30
generations and mapped with restriction enzymes (Figure 1). To
determine in vivo plasmid stability, plasmid DNA was isolated from
mycobacterial colonies and mapped with restriction enzymes 6
weeks post vaccination.
Recombinant MVA expressing Gag (MVA-Gag)
MVA-Gag expressing a matching Gag antigen was used as a
booster. HIV-1 gag was inserted into the Del III region of the
MVA virus genome under the transcriptional control of the
modified-H5 promoter [58]. MVA-Gag was grown on the
chorioallantoic membranes (CAMs) of 10–12 day old chick
embryos and harvested after 72 hours. Titration was performed
in BHK-21 cells, using rabbit anti-vaccinia antibody (Biogenesis,
Poole, UK) and swine anti-rabbit HRP (Dako, Glostrup, Den-
mark) to detect MVA; and sheep anti-p24 antibody (Aalto, Dublin,
Ireland) and anti-sheep HRP (Dako, Glostrup, Denmark) to detect
Gag. Plaques were visualised by the reaction of peroxidase with o-
dianisidine (Sigma, St Louis, USA) in the presence of H2O2 and
counted to determine the virus titre. Irrespective of the antibody
used to detect the plaques identical virus titres were obtained
indicating MVA-Gag to be stable.
Vaccinia viruses (VV) and cells
Vaccinia virus expressing a matched HIV-1 Du422 Gag
subtype C antigen, vT369, (VV-Gag), was manufactured by
Quality Biological (Gaithersburg, MD, USA) and Therion
Biologics, Inc (Cambridge, USA). The New York City Board of
Health (NYCBH) strain of vaccinia, Vaccinia NYCBH, was used
as a control vaccinia (VV-NYCBH). Both viruses were obtained
through the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH. These viruses were amplified on
chick chorioallantoic membranes (CAMs) and titrated in CV-1
cells (Highveld Biological, Johannesburg, SA).
rBCG mouse vaccinations and MVA-Gag boost
The vaccination schedule and all the procedures using female
BALB/c mice (8–10 weeks old in groups of 5) were approved by
the UCT Animal Ethics Committee (reference UCTAEC 01-041)
and performed by a trained animal technologist. The BCG
vaccine and doses used were either 10
5 cfu or 10
7 cfu given via the
intraperitoneal (i.p.) route in 200 ml resuspension medium. For
mice that were primed with the rBCG vaccines and then boosted
with MVA-Gag, the boost was given at week 8 or 12 after the
prime, as an intramuscular (i.m.) vaccination of 10
7 pfu MVA-Gag
in 100 ml PBS with 50 ml injected into each quadriceps muscle.
Bacterial burden and histopathology
Bacterial growth was determined weekly from week 2 to week 5
post vaccination (10
7 cfu, i.p.). Spleens from individual mice were
collected in resuspension medium (2 ml) and homogenized. Ten-
fold serial dilutions of the homogenate were plated on 7H10 agar
containing the appropriate supplements in the presence or absence
of kanamycin (10 ug/ml). Colonies were counted after incubation
at 37uC for approximately 3 weeks.
For histopathology studies livers from individual mice were
harvested at weekly intervals after vaccination (10
7 cfu, i.p.) and
fixed overnight in 10% phosphate buffered formalin, embedded in
paraffin, sectioned and stained with haematoxylin and eosin.
Micrographs were done with an Olympus microscope.
Preparation of splenocytes for immune assays
Spleens were harvested and pooled from 5 mice per group at
weekly intervals after vaccination with the individual BCG
vaccines or 12 days after the MVA-Gag boost to determine
Gag-specific immune responses. A single cell suspension of
splenocytes was prepared then treated with erythrocyte lysing
buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA) for
1 min at room temperature before suspension in R10 culture
medium (RPMI with 10% heat inactivated fetal calf serum (FCS)
containing 15 mM b-mercaptoethanol, 100 U penicillin and
100 mg streptomycin/ml, (Invitrogen, Carlsbad, California,
USA)). Splenocyte aliquots were stained with anti-CD3
+ APC,
anti-CD4
+ FITC and anti-CD8
+ per CP labeled antibodies (BD
Biosciences, The Scientific Group, Johannesburg, SA) to deter-
mine the proportion of CD3
+ cells and CD4
+ and CD8
+
subpopulations by flow cytometry.
IFN-c ELISPOT assay
The Mouse IFN-c ELISPOT set (BD Pharmingen, The
Scientific Group, Johannesburg, SA) was used as per manufac-
turer’s instructions. Splenocytes were plated at 1610
5/well in a
200 ml final volume of R10 alone (to determine background
response) or medium containing an individual peptide (.95%
HPLC pure, Bachem AG, Bubendorf Switzerland) with amino
acid sequence matching BALB/c CD8
+ and CD4
+ epitopes in
Gag, at a concentration of 4 ug/ml. The amino acid sequences of
the peptides were AMQMLKDTI (GagCD8
+ peptide) and
NPPIPVGRIYKRWIILGLNK (GagCD4(13) peptide) and
FRDYVDRFFKTLRAEQATQE (GagCD4(17) peptide) [59–
61]. The reaction was stopped after 22 hours incubation at
37uCi n5 %C O 2, and spots were reacted with the detection
antibody then developed with Nova Red as per the kit instructions.
Spots were counted and analysed using an automatic ELISPOT
reader (CTL technologies, Cleveland, Ohio) and Immunospot
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triplicate reactions. For all experiments the coefficient of variation
of the average (standard deviation (SD) of the average expressed as
a percentage of the average spot numbers) was not more than 9%.
Average spot numbers for responses to peptides that were twice
that of average background spot numbers (absence of peptide)
were considered positive. Values below this cut off were set to zero.
Positive spot numbers were then adjusted to spot forming units
(sfu) per 10
6 splenocytes after background subtraction (not more
than 20 sfu/10
6 splenocytes). The sfu per 10
6 splenocytes for an
individual Gag peptide that arose from either a BCG-Gag or
BCGpan-Gag prime and a MVA-Gag boost, was considered a
positive peptide response arising from the prime-boost regimen if it
was $1.5 fold the individual Gag peptide response for a prime
with the control BCG (BCG-Control or BCGpan-Control) and a
MVA-Gag boost. The sum of sfu per 10
6 splenocytes for responses
to the individual Gag peptides is referred to as the cumulative Gag
peptide response.
Quantification of secreted cytokines
Splenocytes at a concentration of 7.5610
6 per ml R10 culture
medium were cultured (48 h at 37uCi n5 %C O 2 ) in the absence
of peptide (to detect background cytokine release) or with the
individual peptides as used in the IFN-c ELISPOT assay at 4 mg/
ml. The cytokine content of culture supernatants were assayed
using a cytokine bead array assay (BD Pharmingen, The Scientific
Group, Johannesburg, SA) that detected IFN-c, TNF-a, IL-6 and
IL-10. The average of triplicate values was calculated and
expressed as pg cytokine per 10
6 splenocytes. The coefficient of
variation of the average value (SD of the average expressed as a
percentage of the average) was not more than 7%. Cytokine values
were considered positive if greater than twice background values
(not more than 2 pg per 10
6 splenocytes for all assays) and are
reported after background subtraction. Values below the cut off
were set to zero. No IL-10 above background levels could be
detected in the culture supernatant from peptide-stimulated
splenocytes for any of the vaccine regimens. The sum of cytokine
values obtained with the individual Gag peptide stimuli (cumula-
tive cytokine response) for a prime with either BCG-Gag or
BCGpan-Gag and a MVA-Gag boost were considered to be a
positive prime-boost response if $1.5 fold the cumulative response
for a prime with the control BCG (BCG-Control or BCGpan-
Control) and a MVA-Gag boost.
Vaccinia virus challenge
Groups of 10 mice were vaccinated with BCGpan-Gag,
BCGpan-Control (2610
6 cfu, i.p.) or the resuspension medium
used for the rBCG vaccines on day 0 and day 28. Two weeks later
half the mice in each group were challenged with either VV-Gag
or VV-NYCBH (1610
6 pfu, i.p.). Five days after the challenge,
ovaries were collected and pooled from 5 mice per group into
McIlvains buffer. Pooled ovaries were finely chopped and ground
in tenbrook grinders, and cell debris pelleted by low speed
centrifugation. The virus in the supernatant was titrated in CV-1
cells, using serial 10-fold dilutions. Thirty six hours post infection
the cells were stained with Carbol Fuschin and plaques were
counted.
Statistical analysis
Results are expressed as mean and standard deviation of the
mean. Data was statistically analysed using Student’s t test and p
values of ,0.05 were considered significant.
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